Paulo J. Oliveira, Ana M. Urbano

“Oncometabolism: The switchboard of cancer: An editorial”

Otto Warburg, biochemist, FDA, FDG-PET, MRS, Oncometabolism

Otto Warburg's discovery in the 1920s highlighted a unique bioenergetic phenotype in tumor cells, emphasizing their reliance on lactic acid fermentation, which spurred the field of oncometabolism. Oncometabolism has led to advancements like FDG-PET imaging for cancer diagnosis and staging,…

Feb 1^st • 1 min read

Dr Leon Rozen

Clarity is not the same as legibility

You can say something clearly and still not be understood. Understood, in the sense that matters in a decision making forum: whether the reasoning behind the recommendation is accurately read. The recommendation is clear. The words are plain. But the reasoning that produced it remains opaque to the…

Jun 6^th • 0 min read

Dr Leon Rozen

We know more than we can tell

The structural reason good reasoning doesn’t always carry weight

May 19^th • 0 min read

Leon Rozen

What decision-makers actually do when they can't evaluate reasoning directly

Medical Strategy, Medical Leadership, Medical Affairs

There is a scene most advisory professionals will recognise. A recommendation that took weeks to produce — drawing on regulatory environment, market dynamics, scientific evidence, competitor positioning — gets four minutes in a senior forum. A question or two. A decision. The people in that roo…

Apr 12^th • 5 mins read

Leon Rozen

The advice was good. It didn't matter.

Medical Strategy, Medical Leadership, Medical Affairs

There is a particular kind of professional frustration that doesn't have a clean name. It isn't failure — the work was sound. It isn't incompetence. The reasoning was careful, the constraints were weighed, the recommendation was defensible. It is something more specific: the experience of having d…

Apr 12^th • 5 mins read

Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates

hiring, talent demand, job market

As pipelines advance and execution accelerates, pharma and biotech hiring may shift again in 2026, reshaping talent demand.

Feb 4^th • 7 mins read

Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

headcount, reduction, revenue per employee

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.  Among the 17 largest pharma companies analyzed in a Fierce Pharma review of annual reports, only five logged a head count increase in 2025…

Mar 23^rd • 10 mins read

Michael Pietrack

Leadership Lab: Take a Cue From Athletes by Working With an Executive Coach

careers

Executive coaches can help executives take their game to the next level in four key ways, from improving their self-awareness to reshaping their thinking.

Feb 19^th • 6 mins read

Michael Pietrack

Leadership Lab: 5 Steps for Building Your Personal Brand

careers

By building and nurturing a strong personal brand, you can benefit in multiple ways, including enhancing your credibility, attracting opportunities and inspiring investor confidence.

Aug 19^th • 5 mins read

Michael Pietrack

Leadership Lab: How To Spot When Employees Are About To Walk Away

careers

Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework that helps leaders identify when their team members are thinking about heading for the exit—and how to address it.

Oct 22^nd • 7 mins read

Michael Pietrack

Hiring Managers: What Should You Do During a Hiring Freeze?

careers

As we begin 2023, many companies are experiencing hiring freezes. Some hiring managers have a sense of how long the freeze will be, some don’t, but all know that it’s temporary. So, what can hiring managers do during the freeze to stay competitive in the war for talent? Hiring is a competition…

Jan 26^th • 5 mins read

Michael Pietrack

How to Know When to Make a Job Change

careers

In career conversations, one of the most common questions I hear is: “How do I know if it’s time to move on from my company?”  The real decision often comes down to a mix of factors that influence job satisfaction and long-term career growth. That’s why I use the CLAMPS framework. CLAMPS …

Aug 26^th • 5 mins read

Michael Pietrack

The Great Resignation is Now The Great Hesitation

careers

Over the last few years, the employment market has moved through dramatic swings. In 2021 and 2022, millions of professionals left their roles in what became known as The Great Resignation. Jobs were abundant, companies were aggressively hiring, and the perceived level of risk was low. If a new role…

Nov 19^th • 5 mins read

Michael Pietrack

The Four Employment Agreement Questions Every Pharma Executive Must Ask

opinion, career advice, leaderhsip, legal

Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.

Dec 18^th • 6 mins read

Tom Caravela

Interview Differentiator-Be a Story Teller

interview preparation, effective interviewing, behavioral interview questions, storytelling in interviews, successful interview techniques

When you search Google for the words “Interview Preparation,” you will come up with approximately 756,000,000 results. While I am sure you can find an abundance of valuable information, it is very difficult to navigate through all of the content available on the Internet to determine wha…

Mar 22^nd • 1 min read

Tom Caravela

12 Interview Techniques to Help Land Your Next Job

interview preparation, job interview tips, business etiquette, salary negotiation, follow-up after interview

Your next career move could very well be one interview away. Be sure to take every measure to prepare yourself and make the most of the opportunity. According to a recent Simply Hired survey of over 850 Managers, an overwhelming 89% said that “showing lack of preparation” will affect the…

May 12^th • 1 min read

Tom Caravela

MSL Retention – What Matters Most

digital marketing, search engine optimization, keyword analysis, content strategy, online visibility

As the Medical Science Liaison job market continues to become more and more competitive, attrition rates continue to increase as a result. One of the most common questions I receive from MSL Directors and Medical Affairs leaders is, “What can we do to keep our MSLs loyal and motivated?” …

Mar 15^th • 2 mins read

Tom Caravela

7 High-Cost Interview Mistakes that are Easy to Avoid

digital marketing, content strategy, search engine optimization, keyword research, online visibility

Is your job search taking much longer than expected? Have you gone on interviews and feel it went well, but you still didn’t get the job? Interviewing in a competitive job market can be more challenging than one might think. COVID-19 has not made the interview process any easier – instea…

Jul 28^th • 1 min read

Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

single-enantiomer racemic drug pairs, single-enantiomer, FDA, RCTs, generic drugs

Chiral Switching: A strategy where drug manufacturers develop a single-enantiomer formulation from a racemic one to extend market exclusivity, often without proving enhanced efficacy or safety. Objective: To evaluate randomized clinical trials (RCTs) comparing FDA-approved single-enantiomer drugs…

May 6^th • 18 mins read

Xuanyi Li, Elizabeth A. Sigworth, Adrianne H. Wu, Jess Behrens, Shervin A. Etemad, Seema Nagpal, Ronald S. Go, Kristin Wuichet, Eddy J. Chen, Samuel M. Rubinstein, Neeta K. Venepalli, Benjamin F. Tillman, Andrew J. Cowan, Martin W. Schoen, Andrew Malty, J

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Cancer Medical research, Randomized controlled trials, Clinical trial design

Clinical trials are crucial in establishing cancer care standards, but the social dynamics among researchers in this field have not been extensively studied. A social network analysis of authors involved in chemotherapy-based prospective trials from 1946 to 2018 reveals significant insights. The …

Oct 16^th • 12 mins read